The global cell & gene therapy manufacturing services market size is projected to reach USD 11.5 billion by 2027 from USD 5.1 billion in 2022, at a CAGR of 17.5% during the forecast period. Growth in this market is driven by the advanced technologies adopted by the CDMOs to manufacture therapies at full scale. Currently, several CDMOs are expanding their manufacturing capabilities by investing in new technologies to improve their manufacturing services. In addition, the growing partnerships and agreements between pharmaceutical companies and CDMOs is also likely to propel the market during the forecast period.
The global cell & gene therapy manufacturing services market is highly competitive. Key players in the market include Lonza (Switzerland), Catalent, Inc. (US), Thermo Fisher Scientific, Inc. (US), Charles River Laboratories (US), WuXi AppTec (China), Merck KGaA (Germany), Takara Bio Inc. (Japan), Oxford Biomedica (UK), Cell and Gene Therapy Catapult (UK), Genezen (US), FUJIFILM Holdings Corporation (Japan), Nikon Corporation (Japan), The Discovery Labs LLC (US), RoslinCT (Scotland), JRS Pharma (Germany), FinVector (Finland), ABL, Inc. (US), Resilience (US), BioCentriq (US), Porton Advanced Solutions (China), Andelyn Biosciences (US), Forge Biologics (US), Vibalogics (US), Anemocyte Srl (Italy), and ElevateBio (US). Partnerships, agreements, and collaborations are the key growth strategies undertaken by these companies to maintain their positions in the market.
To know about the assumptions considered for the study download the pdf brochure
Lonza is one of the leading players in the life sciences market. The company operates through four business divisions, namely, Capsules & Health Ingredients, Small Molecules, Biologics, and Cell & Gene. The company operates in the cell & gene therapy manufacturing services market through its Cell & Gene business segment.
Lonza has a strong presence across Europe, North and Central America, Latin America, South America, Africa, and the Asia Pacific. Some of the company’s subsidiaries include Lonza America Inc. (US), Lonza Biologics Inc. (US), Lonza Biologics Tuas Pte Ltd. (Singapore), Lonza India Private Ltd., Lonza Japan Ltd., Lonza Costa Rica S.A., and Lonza Shanghai International Trading Ltd. (China).
CATALENT, INC. (US)
Catalent, Inc. offers integrated services, superior delivery technologies, and manufacturing solutions for the life sciences industry to develop and launch pharmaceuticals, biologics, and consumer health products. The company operates through four business segments, namely, Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. Catalent offers cell & gene therapy manufacturing services through the Biologics segment.
The company serves 1,000 customers in approximately 85 countries across North America, South America, Europe, and the Asia Pacific. The key subsidiaries of the company include Paragon Bioservices, Inc. (US), Catalent Micron Technologies, Inc. (US), Catalent Germany Schorndorf GmbH (Germany), Catalent Pharma Solutions Inc. (US), Catalent Italy S.P.A (Italy), and Catalent Australia Pty Ltd. (Australia).
THERMO FISHER SCIENTIFIC (US)
Thermo Fisher Scientific (US) is among the leading players in the cell & gene therapy manufacturing services market. The company has a strong geographic footprint serving over 400,000 customers in pharmaceutical and biotech companies. The leading position of Thermo Fisher in this market can be attributed to its broad product portfolio, vast experience, and vast distribution channel. Thermo Fisher also strengthened its presence in the market through acquisitions. For instance, in 2019, Thermo Fisher Scientific acquired Brammer Bio, a company engaged in viral vector manufacturing for gene and cell therapies, for USD 1.7 billion. The company’s distribution network comprises a broad sales force and a global network of resellers and distributors. Its extensive R&D activities enable it to increase its depth of capabilities in technologies, software, and services
Cell & Gene Therapy Manufacturing Services Market by Type (Allogeneic, Autologous, Viral Vector, Non-viral vector), Indication (Oncology, Orthopedic, Ophthalmology), Application (Clinical, Commercial), End User (Pharma, Biotech) - Global Forecast to 2027
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.SEND ME A FREE SAMPLE